-
Drug delivery system based on metal-organic framework improved 5-Fluorouracil against spring viremia of carp virus Antivir. Res. (IF 7.6) Pub Date : 2024-04-10 Liang Zhao, Wei-Ze Wang, Tian-Tian Jiang, Tian-Zi Sun, Bo Liu, Bin Zhu
Spring viremia of carp virus (SVCV), as a high pathogenicity pathogen, has seriously restricts the healthy and sustainable development of cyprinid farming industry. In this study, we selected 5-Fluorouracil (5-Fu) as the drug model based on zeolitic imidazolate framework-8 (ZIF-8) to construct a drug delivery system (5-Fu@ZIF-8), and the anti-SVCV activity was detected and . The results showed 5-Fu@ZIF-8
-
Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice Antivir. Res. (IF 7.6) Pub Date : 2024-04-10 Mingyang Guo, Jianqing Peng, Pengcheng Guo, Qin Wang, Lin Zhang, Huyan Shen, Fang Chen, Pingping Zhang, Siyu Lin, Han Gao, Hong Peng, Rong Mou, Jiandong Huang, Jianxin Wang, Yu-Si Luo, Ke Zhang
Human respiratory syncytial virus (RSV) is a common cause of respiratory infections in infants, young children, and elderly people. However, there are no effective treatments or vaccines available in most countries. In this study, we explored the anti-RSV potential of 2, 4-Di-tert-butylphenol (2, 4-DTBP), a compound derived from Thunb. To overcome the poor solubility of 2, 4-DTBP, we encapsulated it
-
Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses Antivir. Res. (IF 7.6) Pub Date : 2024-04-09 Beatrice Tolksdorf, Julian Heinze, Daniela Niemeyer, Viola Röhrs, Johanna Berg, Christian Drosten, Jens Kurreck
-
Characterisation of ten NS2B-NS3 proteases: Paving the way for pan-flavivirus drugs Antivir. Res. (IF 7.6) Pub Date : 2024-04-04 Saan Voss, Jörg Rademann, Christoph Nitsche
-
Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp Antivir. Res. (IF 7.6) Pub Date : 2024-04-03 Gary Wong, Kathrina Mae Bienes, Ara XIII, Hugues Fausther-Bovendo, Gary P. Kobinger
In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013–2016 West Africa outbreak. This review recounts the history
-
Early application of IFNγ mediated the persistence of HBV in an HBV mouse model Antivir. Res. (IF 7.6) Pub Date : 2024-03-30 Jingjiao Song, Xiliang Sun, Yun Zhou, Sheng Li, Jun Wu, Lu Yang, Di Zhou, Yan Yang, Anding Liu, Mengji Lu, Roggendorf Michael, Li Qin, Dongliang Yang
The antiviral activity of interferon gamma (IFNγ) against hepatitis B virus (HBV) was demonstrated both and in a previous study. IFNγ can suppress HBV replication by accelerating the decay of replication-competent nucleocapsids of HBV. However, in this study, we found that the direct application of the mouse IFNγ (mIFNγ) expression plasmid to the liver of an HBV hydrodynamic injection (HI) mouse model
-
Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice Antivir. Res. (IF 7.6) Pub Date : 2024-03-30 Jannatul Ruhan Raha, Ki-Hye Kim, Noopur Bhatnagar, Rong Liu, Chau Thuy Tien Le, Bo Ryoung Park, Phillip Grovenstein, Surya Sekhar Pal, Eun-Ju Ko, Chong Hyun Shin, Bao-Zhong Wang, Sang-Moo Kang
The conventional inactivated split seasonal influenza vaccine offers low efficacy, particularly in the elderly and against antigenic variants. Here, to improve the efficacy of seasonal vaccination for the elderly population, we tested whether supplementing seasonal bivalent (H1N1 + H3N2) split (S) vaccine with M2 ectodomain repeat and multi-subtype consensus neuraminidase (NA) proteins (N1 NA + N2
-
Glucocorticoid receptor and specificity protein 1 (Sp1) or Sp3, but not the antibiotic Mithramycin A, stimulates human alphaherpesvirus 1 (HSV-1) replication Antivir. Res. (IF 7.6) Pub Date : 2024-03-29 Fouad S. El-Mayet, Vanessa Claire Santos, Nishani Wijesekera, Sydney Lubbers, Kelly S. Harrison, Hafez Sadeghi, Clinton Jones
Following acute human alphaherpesvirus 1 (HSV-1) infection of oral-facial mucosal surfaces, sensory neurons in trigeminal ganglia (TG) are important sites for life-long latency. Neurons in the central nervous system, including brainstem, also harbor viral genomes during latency. Periodically, certain cellular stressors trigger reactivation from latency, which can lead to recurrent HSV-1 disease: herpes
-
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses Antivir. Res. (IF 7.6) Pub Date : 2024-03-28 Andrei E. Siniavin, Vladimir A. Gushchin, Natal'ya S. Shastina, Elizaveta S. Darnotuk, Sergey I. Luyksaar, Leonid I. Russu, Anna M. Inshakova, Elena V. Shidlovskaya, Daria V. Vasina, Nadezhda A. Kuznetsova, Daria M. Savina, Ilya D. Zorkov, Inna V. Dolzhikova, Anna B. Sheremet, Denis Y. Logunov, Nailya A. Zigangirova, Alexander L. Gintsburg
The spread of COVID-19 continues due to genetic variation in SARS-CoV-2. Highly mutated variants of SARS-CoV-2 have an increased transmissibility and immune evasion. Due to the emergence of various new variants of the virus, there is an urgent need to develop broadly effective specific drugs for therapeutic strategies for the prevention and treatment of COVID-19. Molnupiravir (EIDD-2801, MK-4482),
-
DDX20 positively regulates the interferon pathway to inhibit viral infection Antivir. Res. (IF 7.6) Pub Date : 2024-03-28 Zhiqiang Chen, Jinyu Zhang, Tingting Feng, Xiujuan Wang, Shimeng Zhou, Wen Pan, Zhengrong Chen, Yongdong Yan, Jianfeng Dai
The DEAD-box (DDX) family comprises RNA helicases characterized by the conserved sequence D(Asp)-E(Glu)-A(Ala)-D(Asp), participating in various RNA metabolism processes. Some DDX family members have been identified for their crucial roles in viral infections. In this study, RNAi library screening of the DDX family unveiled the antiviral activity of DDX20. Knockdown of DDX20 enhanced the replication
-
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors Antivir. Res. (IF 7.6) Pub Date : 2024-03-28 Kaustav Khatua, Yugendar R. Alugubelli, Kai S. Yang, Veerabhadra R. Vulupala, Lauren R. Blankenship, Demonta Coleman, Sandeep Atla, Sankar P. Chaki, Zhi Zachary Geng, Xinyu R. Ma, Jing Xiao, Peng-Hsun Chen, Chia-Chuan D. Cho, Shivangi Sharma, Erol C. Vatansever, Yuying Ma, Ge Yu, Benjamin W. Neuman, Shiqing Xu, Wenshe Ray Liu
-
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals Antivir. Res. (IF 7.6) Pub Date : 2024-03-26 Jimena Pérez-Vargas, Gabriel Lemieux, Connor A.H. Thompson, Antoine Désilets, Siobhan Ennis, Guang Gao, Danielle G. Gordon, Annika Lea Schulz, Masahiro Niikura, Ivan Robert Nabi, Mel Krajden, Pierre-Luc Boudreault, Richard Leduc, François Jean
-
Preclinical animal models to evaluate therapeutic antiviral antibodies Antivir. Res. (IF 7.6) Pub Date : 2024-03-26 Amse De Meyer, Philip Meuleman
-
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies Antivir. Res. (IF 7.6) Pub Date : 2024-03-21 Wenli Sun, Yanling Wu, Tianlei Ying
Monoclonal antibody-based therapeutics have achieved remarkable success in treating a wide range of human diseases. However, conventional systemic delivery methods have limitations in insufficient target tissue permeability, high costs, repeated administrations, etc. Novel technologies have been developed to address these limitations and further enhance antibody therapy. Local antibody delivery via
-
Corrigendum to “Avasimibe can cooperate with a DC-targeting and integration-deficient lentivector to induce stronger HBV specific T cytotoxic response by regulating cholesterol metabolism” Antiviral Res. 2023 Aug:216:105662] Antivir. Res. (IF 7.6) Pub Date : 2024-03-19 Siyuan Ma, Mengjiao Lv, Xiaohua Chen, Guoqing Zang, Zhenghao Tang, Yi Zhang, Weiwei Hu
-
A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication Antivir. Res. (IF 7.6) Pub Date : 2024-03-14 Christopher Moon, Eleanor Porges, Adam Roberts, Joanna Bacon
Antiviral therapeutics are highly effective countermeasures for the treatment of coronavirus disease 2019 (COVID-19). However, development of resistance to antivirals undermines their effectiveness. Combining multiple antivirals during patient treatment has the potential to overcome the evolutionary selective pressure towards antiviral resistance, as well as provide a more robust and efficacious treatment
-
Caffeic acid phenethyl ester: an effective antiviral agent against porcine reproductive and Respiratory Syndrome Virus Antivir. Res. (IF 7.6) Pub Date : 2024-03-13 Zhanding Cui, Jing Zhang, Jinlong Wang, Jinlong Liu, Pu Sun, Jiaoyang Li, Guoxiu Li, Ying Sun, Juanbin Ying, Kun Li, Zhixun Zhao, Hong Yuan, Xingwen Bai, Xueqing Ma, Pinghua Li, Yuanfang Fu, Huifang Bao, Dong Li, Qiang Zhang, Zaixin Liu, Yimei Cao, Zengjun Lu
Porcine Reproductive and Respiratory Syndrome (PRRS) presents a formidable viral challenge in swine husbandry. Confronting the constraints of existing veterinary pharmaceuticals and vaccines, this investigation centers on Caffeic Acid Phenethyl Ester (CAPE) as a prospective clinical suppressant for the Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The study adopts an integrated methodology
-
β-D-N4-hydroxycytidine (NHC, EIDD-1931) inhibits chikungunya virus replication in mosquito cells and ex vivo Aedes aegypti guts, but not when ingested during blood-feeding Antivir. Res. (IF 7.6) Pub Date : 2024-03-13 Ana Lucia Rosales-Rosas, Alina Soto, Lanjiao Wang, Raf Mols, Albin Fontaine, Aboubakar Sanon, Patrick Augustijns, Leen Delang
Chikungunya virus (CHIKV) is a mosquito-borne virus transmitted by mosquitoes. While there are no antiviral therapies currently available to treat CHIKV infections, several licensed oral drugs have shown significant anti-CHIKV activity in cells and in mouse models. However, the efficacy in mosquitoes has not yet been assessed. Such cross-species antiviral activity could be favorable, since virus inhibition
-
Construction of exosome-loaded LL-37 and its protection against zika virus infection Antivir. Res. (IF 7.6) Pub Date : 2024-03-08 Chen Wang, Min Li, Xiaohui Xia, Yuxuan Fu, Yi Wang, Wei Xu, Hongqi Wei, Lin Wei
Zika virus (ZIKV) is an enveloped, single-stranded and positive-stranded RNA virus of the genus in the family . ZIKV can cross the placental barrier and infect the fetus, causing microcephaly, congenital ZIKV syndrome, and even fetal death. ZIKV infection can also lead to testicular damage and male sterility. But no effective drugs and vaccines are available up to now. Previous studies have shown that
-
Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines Antivir. Res. (IF 7.6) Pub Date : 2024-03-07 Jiin Felgner, Elizabeth Clarke, Jenny E. Hernandez-Davies, Sharon Jan, Ariel S. Wirchnianski, Aarti Jain, Rie Nakajima, Algimantas Jasinskas, Erwin Strahsburger, Kartik Chandran, Steven Bradfute, D. Huw Davies
Currently, there are two approved vaccine regimens designed to prevent Ebola virus (EBOV) disease (EVD). Both are virus-vectored, and concerns about cold-chain storage and pre-existing immunity to the vectors warrant investigating additional vaccine strategies. Here, we have explored the utility of adjuvanted recombinant glycoproteins (GPs) from ebolaviruses Zaire (EBOV), Sudan (SUDV), and Bundibugyo
-
A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2 Antivir. Res. (IF 7.6) Pub Date : 2024-03-05 Weiqi Wang, Shen Wang, Xianyong Meng, Yongkun Zhao, Nan Li, Tiecheng Wang, Na Feng, Feihu Yan, Xianzhu Xia
-
Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A Antivir. Res. (IF 7.6) Pub Date : 2024-03-05 Maja Klevanski, Heeyoung Kim, Mike Heilemann, Thomas Kuner, Ralf Bartenschlager
-
SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential Antivir. Res. (IF 7.6) Pub Date : 2024-03-05 Magdalena Bandyszewska, Magdalena Ambrożek-Latecka, Grażyna Hoser, Małgorzata Grzanka, Franziska Hornung, Stefanie Deinhardt-Emmer, Tomasz Skirecki
The emerging SARS-CoV-2 variants are evolving to evade human immunity and differ in their pathogenicity. While evasion of the variants from adaptive immunity is widely investigated, there is a paucity of knowledge about their interactions with innate immunity. Inflammasome assembly is one of the most potent mechanisms of the early innate response to viruses, but when it is inappropriate, it can perpetuate
-
The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance Antivir. Res. (IF 7.6) Pub Date : 2024-03-02 André Schreiber, Franziska Rodner, Nicole Oberberg, Darisuren Anhlan, Stefan Bletz, Alexander Mellmann, Oliver Planz, Stephan Ludwig
-
Third International Conference on Crimean-Congo Hemorrhagic Fever in Thessaloniki, Greece, September 19–21, 2023 Antivir. Res. (IF 7.6) Pub Date : 2024-02-29 Stephen R. Welch, Aura R. Garrison, Dennis A. Bente, Felicity Burt, Jake D'Addiego, Stephanie Devignot, Stuart Dowall, Kerstin Fischer, David W. Hawman, Roger Hewson, Ali Mirazimi, Lisa Oestereich, Zati Vatansever, Jessica R. Spengler, Anna Papa
The Third International Conference on Crimean-Congo Hemorrhagic Fever (CCHF) was held in Thessaloniki, Greece, September 19–21, 2023, bringing together a diverse group of international partners, including public health professionals, clinicians, ecologists, epidemiologists, immunologists, and virologists. The conference was attended by 118 participants representing 24 countries and the World Health
-
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 season Antivir. Res. (IF 7.6) Pub Date : 2024-02-29 Takeyuki Goto, Naoki Kawai, Takuma Bando, Yoshio Takasaki, Shizuo Shindo, Naoki Tani, Yong Chong, Hideyuki Ikematsu
While clinical trials have illuminated both the virological and clinical efficacy of baloxavir for influenza and post-treatment viral resistance, these aspects warrant further study in real-world settings. In response, we executed a prospective, observational study of the Japanese 2022–2023 influenza season. A cohort of 73 A(H3N2)-diagnosed outpatients—36 treated with baloxavir, 20 with oseltamivir
-
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2 Antivir. Res. (IF 7.6) Pub Date : 2024-02-28 Haruaki Nobori, Keiko Baba, Takayuki Kuroda, Kaoru Baba, Kazumi Matsumoto, Shinpei Yoshida, Ryosuke Watari, Yuki Tachibana, Teruhisa Kato, Keita Fukao
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of coronavirus disease 2019 (COVID-19) and continues to be a major health concern worldwide. Strategies to protect individuals at high risk of COVID-19 are critical but are currently a largely unmet need. We evaluated the oral antiviral drug ensitrelvir, which specifically targets the SARS-CoV-2 3CL protease, for
-
The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants Antivir. Res. (IF 7.6) Pub Date : 2024-02-26 Aleksandr Ianevski, Irene Trøen Frøysa, Hilde Lysvand, Carlemi Calitz, Teemu Smura, Hans-Johnny Schjelderup Nilsen, Erling Høyer, Jan Egil Afset, Adithya Sridhar, Katja C. Wolthers, Eva Zusinaite, Tanel Tenson, Reet Kurg, Valentyn Oksenych, Angel S. Galabov, Adelina Stoyanova, Magnar Bjørås, Denis E. Kainov
Enteroviruses are a significant global health concern, causing a spectrum of diseases from the common cold to more severe conditions like hand-foot-and-mouth disease, meningitis, myocarditis, pancreatitis, and poliomyelitis. Current treatment options for these infections are limited, underscoring the urgent need for effective therapeutic strategies. To find better treatment option we analyzed toxicity
-
Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection Antivir. Res. (IF 7.6) Pub Date : 2024-02-24 Hongtao Li, Meng Sun, Fuzhi Lei, Jinfeng Liu, Xixiang Chen, Yaqi Li, Ying Wang, Jiani Lu, Danmei Yu, Yueqiu Gao, Jianrong Xu, Hongzhuan Chen, Man Li, Zhigang Yi, Xiao He, Lili Chen
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been ongoing for more than three years and urgently needs to be addressed. Traditional Chinese medicine (TCM) prescriptions have played an important role in the clinical treatment of patients with COVID-19 in China. However, it is difficult to uncover the potential molecular mechanisms
-
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients Antivir. Res. (IF 7.6) Pub Date : 2024-02-23 Yannick Debing, Hannah Vanrusselt, Lars Degrauwe, Daniel Apolônio Silva de Oliveira, Christopher Kinyanjui Kariuki, Ebanja Joseph Ebwanga, Shahbaz Bashir, Wouter Merckx, Santhosh Kumar Thatikonda, Vivek Rajwanshi, Vikrant Gohil, Jin Hong, Dieudonné Buh Kum, Abel Acosta Sanchez, Sushmita Chanda, Lawrence M. Blatt, Andreas Jekle, Julian A. Symons, David B. Smith, Pierre Raboisson, Tse-I Lin, Leonid Beigelman
Nucleic acid polymers (NAPs) are an attractive treatment modality for chronic hepatitis B (CHB), with REP2139 and REP2165 having shown efficacy in CHB patients. A subset of patients achieve functional cure, whereas the others exhibit a moderate response or are non-responders. NAP efficacy has been difficult to recapitulate in animal models, with the duck hepatitis B virus (DHBV) model showing some
-
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses Antivir. Res. (IF 7.6) Pub Date : 2024-02-20 Maria Giulia Bigotti, Katja Klein, Esther S. Gan, Maria Anastasina, Simon Andersson, Olli Vapalahti, Pekka Katajisto, Maximilian Erdmann, Andrew D. Davidson, Sarah J. Butcher, Ian Collinson, Eng Eong Ooi, Giuseppe Balistreri, Andrea Brancaccio, Yohei Yamauchi
The COVID-19 pandemic has shown the need to develop effective therapeutics in preparedness for further epidemics of virus infections that pose a significant threat to human health. As a natural compound antiviral candidate, we focused on α-dystroglycan, a highly glycosylated basement membrane protein that links the extracellular matrix to the intracellular cytoskeleton. Here we show that the N-terminal
-
Mechanism of action of phthalazinone derivatives against rabies virus Antivir. Res. (IF 7.6) Pub Date : 2024-02-18 Victoire Perraud, Bart Vanderhoydonck, Guillaume Bouvier, Guilherme Dias de Melo, Amuri Kilonda, Mohamed Koukni, Dirk Jochmans, Sophie Rogée, Youcef Ben Khalifa, Lauriane Kergoat, Julien Lannoy, Tina Van Buyten, Nadia Izadi-Pruneyre, Patrick Chaltin, Johan Neyts, Arnaud Marchand, Florence Larrous, Hervé Bourhy
-
Neutralizing antibodies to block viral entry and for identification of entry inhibitors Antivir. Res. (IF 7.6) Pub Date : 2024-02-17 Ee Hong Tam, Yu Peng, Megan Xin Yan Cheah, Chuan Yan, Tianshu Xiao
Neutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have been extensively used to prevent and treat a wide variety of viral infections, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Immunodeficiency Virus (HIV), Dengue Virus (DENV) and Hepatitis
-
Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids Antivir. Res. (IF 7.6) Pub Date : 2024-02-17 Nanci Santos-Ferreira, Jana Van Dycke, Winston Chiu, Johan Neyts, Jelle Matthijnssens, Joana Rocha-Pereira
Human norovirus (HuNoV) and human rotavirus (HRV) are the leading causes of gastrointestinal diarrhea. There are no approved antivirals and rotavirus vaccines are insufficient to cease HRV associated mortality. Furthermore, treatment of chronically infected immunocompromised patients is limited to off-label compassionate use of repurposed antivirals with limited efficacy, highlighting the urgent need
-
Porcine interferon-α linked to the porcine IgG-Fc induces prolonged and broad-spectrum antiviral effects against foot-and-mouth disease virus Antivir. Res. (IF 7.6) Pub Date : 2024-02-14 Gyeongmin Lee, Aro Kim, Hyo Rin Kang, Ji-Hyeon Hwang, Jong-Hyeon Park, Min Ja Lee, Byounghan Kim, Su-Mi Kim
Foot-and-mouth disease (FMD) is an economically important disease, and the FMD virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled through vaccination. However, commercial FMD vaccines are only effective 4–7 days after vaccination. Furthermore, FMDV comprises seven serotypes and various topotypes, and these aspects should be considered when selecting a vaccine. Antiviral
-
Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus Antivir. Res. (IF 7.6) Pub Date : 2024-02-11 Xiaoli Zhang, Yiping Xia, Peibo Li, Zhongnan Wu, Ruilin Li, Jialiao Cai, Yubo Zhang, Guocai Wang, Yaolan Li, Wei Tang, Weiwei Su
Influenza therapeutics with new targets and modes of action are urgently needed due to the frequent emergence of mutants resistant to currently available anti-influenza drugs. Here we report the and anti-influenza A virus activities of cyperenoic acid, a natural compound, which was isolated from a Chinese medicine Geise. Cyperenoic acid could potently suppress H1N1, H3N2 and H9N2 virus replication
-
-
Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses Antivir. Res. (IF 7.6) Pub Date : 2024-02-06 Divya Sinha, Melyssa Yaugel-Novoa, Louis Waeckel, Stéphane Paul, Stéphanie Longet
Mucosal immunity has regained its spotlight amidst the ongoing Coronavirus disease 19 (COVID-19) pandemic, with numerous studies highlighting the crucial role of mucosal secretory IgA (SIgA) in protection against Severe acute respiratory syndrome coronavirus-2 or SARS-CoV-2 infections. The observed limitations in the efficacy of currently authorized COVID-19 vaccines in inducing effective mucosal immune
-
Identification and assessment of the 1,6-dihydroxy-pyridin-2-one moiety as privileged scaffold for HBV ribonuclease H inhibition Antivir. Res. (IF 7.6) Pub Date : 2024-02-05 Erofili Giannakopoulou, Vasiliki Pardali, Tiffany C. Edwards, Molly Woodson, Razia Tajwar, John E. Tavis, Grigoris Zoidis
-
Miltefosine reduces coxsackievirus B3 lethality of mice with enhanced STAT3 activation Antivir. Res. (IF 7.6) Pub Date : 2024-02-02 Chun Yu Zhang, Cheng-Huei Hung, Yi-Ling Hsiao, Tung-Miao Chang, Yu-Chieh Su, Li-Chiu Wang, Shih-Min Wang, Shun-Hua Chen
Coxsackievirus B3 (CVB3), one serotype of enteroviruses, can induce fatal myocarditis and hepatitis in neonates, but both treatment and vaccine are unavailable. Few reports tested antivirals to reduce CVB3. Several antivirals were developed against other enterovirus serotypes, but these antivirals failed in clinical trials due to side effects and drug resistance. Repurposing of clinical drugs targeting
-
An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses Antivir. Res. (IF 7.6) Pub Date : 2024-02-02 Yuanhong Wang, Yun Liu, Junna Wang, Miao Zhang, Xiaoying Deng, Junhan Song, Jie Zhu, Lingxue Yu, Guoxin Li, Guangqing Liu
Feline coronavirus (FCoV) is an unsegmented, single-stranded RNA virus belonging to the genus. It can cause fatal feline infectious peritonitis (FIP) in cats of any ages. Currently, there are no effective prevention and control measures to against FCoV. In this study, we developed a recombinant adenovirus vaccine, AD5-N, based on the nucleocapsid(N) protein of FCoV. The immunogenicity of AD5-N was
-
Therapeutic antibodies and alternative formats against SARS-CoV-2 Antivir. Res. (IF 7.6) Pub Date : 2024-02-01 Rahel R. Winiger, Laurent Perez
The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines and therapeutics to confront infection, the virus remains a threat. The ancestor viral strain has evolved into several variants of concern, with the Omicron variant now having many distinct sublineages. Consequently, most available antibodies
-
Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors Antivir. Res. (IF 7.6) Pub Date : 2024-01-28 Marta Trevisan, Anna Pianezzola, Marco Onorati, Lorenzo Apolloni, Mauro Pistello, Ravit Arav-Boger, Giorgio Palù, Beatrice Mercorelli, Arianna Loregian
-
Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results Antivir. Res. (IF 7.6) Pub Date : 2024-01-25 Roza Izmailyan, Mher Matevosyan, Hamlet Khachatryan, Anastasiya Shavina, Smbat Gevorgyan, Artur Ghazaryan, Irina Tirosyan, Yeva Gabrielyan, Marusya Ayvazyan, Boris Martirosyan, Vardan Harutyunyan, Hovakim Zakaryan
In this research, we employed a deep reinforcement learning (RL)-based molecule design platform to generate a diverse set of compounds targeting the neuraminidase (NA) of influenza A and B viruses. A total of 60,291 compounds were generated, of which 86.5 % displayed superior physicochemical properties compared to oseltamivir. After narrowing down the selection through computational filters, nine compounds
-
Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains Antivir. Res. (IF 7.6) Pub Date : 2024-01-24 Hawa Sophia Bouzidi, Jean-Sélim Driouich, Raphaëlle Klitting, Ornéllie Bernadin, Géraldine Piorkowski, Rayane Amaral, Laurent Fraisse, Charles E. Mowbray, Ivan Scandale, Fanny Escudié, Eric Chatelain, Xavier de Lamballerie, Antoine Nougairède, Franck Touret
Since the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid®) has shown the best results in clinical trials and the greatest robustness against variants. A second SARS-CoV-2 protease inhibitor, ensitrelvir (Xocova®), has been developed. Ensitrelvir, currently in Phase 3, was approved
-
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome Antivir. Res. (IF 7.6) Pub Date : 2024-01-24 Mariia S. Bogacheva, Suvi Kuivanen, Swapnil Potdar, Antti Hassinen, Sini Huuskonen, Ina Pöhner, Tamara J. Luck, Laura Turunen, Michaela Feodoroff, Leonora Szirovicza, Kirsi Savijoki, Jani Saarela, Päivi Tammela, Lassi Paavolainen, Antti Poso, Markku Varjosalo, Olli Kallioniemi, Vilja Pietiäinen, Olli Vapalahti
-
A lipid index for risk of hyperlipidemia caused by anti-retroviral drugs Antivir. Res. (IF 7.6) Pub Date : 2024-01-23 Mari Shimura, Nobuyo Higashi-Kuwata, Asuka Fujiwara, Mai Taniguchi, Takayuki Ichinose, Fumie Hamano, Masaaki Uematsu, Takato Inoue, Satoshi Matsuyama, Takahiro Suzuki, Arun K. Ghosh, Hideo Shindou, Takao Shimuzu, Hiroaki Mitsuya
HIV-associated lipodystrophy has been reported in people taking anti-retroviral therapy (ART). Lipodystrophy can cause cardiovascular diseases, affecting the quality of life of HIV-infected individuals. In this study, we propose a pharmacological lipid index to estimate the risk of hyperlipidemia caused by anti-retroviral drugs. Lipid droplets were stained in cells treated with anti-retroviral drugs
-
Antiviral effect of peptoids on hepatitis B virus infection in cell culture Antivir. Res. (IF 7.6) Pub Date : 2024-01-23 Asako Murayama, Hitomi Igarashi, Norie Yamada, Hussein Hassan Aly, Natalia Molchanova, Jennifer S. Lin, Hironori Nishitsuji, Kunitada Shimotohno, Masamichi Muramatsu, Annelise E. Barron, Takanobu Kato
Although antimicrobial peptides have been shown to inactivate viruses through disruption of their viral envelopes, clinical use of such peptides has been hampered by a number of factors, especially their enzymatically unstable structures. To overcome the shortcomings of antimicrobial peptides, peptoids (sequence-specific -substituted glycine oligomers) mimicking antimicrobial peptides have been developed
-
HAND2 suppresses favipiravir efficacy in treatment of Borna disease virus infection Antivir. Res. (IF 7.6) Pub Date : 2024-01-21 Da Teng, Keiji Ueda, Tomoyuki Honda
Borna disease virus (BoDV-1) is a bornavirus prototype that infects the central nervous system of various animal species and can cause fatal encephalitis in various animals including humans. Among the reported anti-BoDV-1 treatments, favipiravir (T-705) is one of the best candidates since it has been shown to be effective in reducing various bornavirus titers in cell culture. However, T-705 effectiveness
-
An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity. Antivir. Res. (IF 7.6) Pub Date : 2024-01-19 Adi Idris, Aroon Supramaniam, Yaman Tayyar, Gabrielle Kelly, Nigel A.J. McMillan, Kevin V. Morris
There remains a striking overall mortality burden of COVID-19 worldwide. Given the waning effectiveness of current SARS-CoV-2 antivirals due to the rapid emergence of new variants of concern (VOC), we employed a direct-acting molecular therapy approach using gene silencing RNA interference (RNAi) technology. In this study, we developed and screened several ultra-conserved small-interfering RNAs (siRNAs)
-
High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection Antivir. Res. (IF 7.6) Pub Date : 2024-01-19 Avery C.S. Bond, Mason A. Crocker, Michael P. Wilczek, Jeanne K. DuShane, Amanda L. Sandberg, Lucas J. Bennett, Nicholas R. Leclerc, Melissa S. Maginnis
JC polyomavirus (JCPyV) is a nonenveloped, double-stranded DNA virus that infects the majority of the population. Immunocompetent individuals harbor infection in their kidneys, while severe immunosuppression can result in JCPyV spread to the brain, causing the neurodegenerative disease progressive multifocal leukoencephalopathy (PML). Due to a lack of approved therapies to treat JCPyV and PML, the
-
Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance Antivir. Res. (IF 7.6) Pub Date : 2024-01-18 Martina Richter, Kristin Döring, Dieter Blaas, Olga Riabova, Maria Khrenova, Elena Kazakova, Anna Egorova, Vadim Makarov, Michaela Schmidtke
-
Activation of cGAS-STING suppresses coxsackievirus replication via interferon-dependent signaling Antivir. Res. (IF 7.6) Pub Date : 2024-01-18 Yasir Mohamud, Cathy Fu, Yiyun Michelle Fan, Yizhuo Lyanne Zhang, Jing Fei Carly Lin, Sinwoo Wendy Hwang, Zhihan Claire Wang, Honglin Luo
Coxsackievirus B3 (CVB3) is a non-enveloped, single-stranded, positive RNA virus known for its role in provoking inflammatory diseases that affect the heart, pancreas, and brain, leading to conditions such as myocarditis, pancreatitis, and meningitis. Currently, there are no FDA-approved drugs treating CVB3 infection; therefore, identifying potential molecular targets for antiviral drug development
-
-
Promises and challenges of single-domain antibodies to control influenza Antivir. Res. (IF 7.6) Pub Date : 2024-01-12 Arne Matthys, Xavier Saelens
-
TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences Antivir. Res. (IF 7.6) Pub Date : 2024-01-09 Tea Govednik, Duško Lainšček, Urška Kuhar, Marva Lachish, Sandra Janežič, Malan Štrbenc, Uroš Krapež, Roman Jerala, Daphne Atlas, Mateja Manček-Keber
-
Chromatin binding protein HMGN1 promotes HBV cccDNA transcription and replication by regulating the phosphorylation of histone 3 Antivir. Res. (IF 7.6) Pub Date : 2024-01-03 Tan Ming, Liu Yuting, Dong Meiling, Cheng Shengtao, Ren Jihua, Zhang Hui, Chen Wanjin, Li Dian, Gao Tingting, Chen Juan, Zhang Zhenzhen
-
Genetically modified pigs lacking CD163 PSTII-domain-coding exon 13 are completely resistant to PRRSV infection Antivir. Res. (IF 7.6) Pub Date : 2024-01-04 Brianna Salgado, Rafael Bautista Rivas, Derek Pinto, Tad S. Sonstegard, Daniel F. Carlson, Kyra Martins, Jonathan R. Bostrom, Yamlak Sinebo, Raymond R.R. Rowland, Alberto Brandariz-Nuñez
CD163 expressed on cell surface of porcine alveolar macrophages (PAMs) serves as a cellular entry receptor for porcine reproductive and respiratory syndrome virus (PRRSV). The extracellular portion of CD163 contains nine scavenger receptor cysteine-rich (SRCR) and two proline-serine-threonine (PST) domains. Genomic editing of pigs to remove the entire CD163 or just the SRCR5 domain confers resistance
-
Oral USC-093, a novel homoserinamide analogue of the tyrosinamide (S)-HPMPA prodrug USC-087 has decreased nephrotoxicity while maintaining antiviral efficacy against human adenovirus infection of Syrian hamsters Antivir. Res. (IF 7.6) Pub Date : 2024-01-06 Ann E. Tollefson, Samantha B. Riemann, Baoling Ying, Jacqueline F. Spencer, Justin M. Overhulse, Boris A. Kashemirov, William S.M. Wold, Charles E. McKenna, Karoly Toth
Adenovirus infections of immunocompromised humans are a significant source of morbidity and mortality. Presently, there is no drug specifically approved for the treatment of adenovirus infections by the FDA. The state-of-the-art treatment of such infections is the off-label use of cidofovir, an acyclic nucleotide phosphonate. While cidofovir inhibits adenovirus replication, it has dose-limiting kidney
-
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models. Antivir. Res. (IF 7.6) Pub Date : 2024-01-06 Inés García-Rodríguez, Giulia Moreni, Pamela E. Capendale, Lance Mulder, Ikrame Aknouch, Renata Vieira de Sá, Nina Johannesson, Eline Freeze, Hetty van Eijk, Gerrit Koen, Katja C. Wolthers, Dasja Pajkrt, Adithya Sridhar, Carlemi Calitz